700 J ournal of Medicinal Chemistry, 2003, Vol. 46, No. 5
Katayama et al.
(6) (a) Leeson, P. D.; Iversen, L. L. The glycine site on the NMDA
receptor: Structure-activity relationships and therapeutic po-
tential. J . Med. Chem. 1994, 37, 4053-4067. (b) Rowley, M.;
Kulagowski, J . J .; Watt, A. P.; Rathbone, D.; Stevenson, G. I.;
Carling, R. W.; Baker, R.; Marshall, G. R.; Kemp, J . A.; Foster,
A. C.; Grimwood, S.; Hargreaves, R.; Hurley, C.; Saywell, K. L.;
Tricklebank, M. D.; Leeson, P. D. Effect of plasma protein
binding on in vivo activity and brain penetration of glycine/
NMDA receptor atagonists. J . Med. Chem. 1997, 40, 4053-4068,
and references therein.
(7) (a) Keana, J . F. W.; Kher, S. M.; Xiong, Cai, S.; Dinsmore, C.
M.; Glenn, A. G.; Guastella, J .; Huang, J . C.; Ilyin, V.; Lu, Y.;
Mouser, P. L.; Woodward, R. M.; Weber, E. Synthesis and
structure-activity relationships of substituted 1,4-dihydroqui-
noxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA)
receptor glycine sites and non-NMDA glutamate receptors. J .
Med. Chem. 1995 38, 4367-4379. (b) Lutfy, K.; Weber, E.
Attenuation of nociceptive responses by ACEA 1021, a competi-
tive NMDA receptor/glycine site antagonist, in the mice. Brain
Res. 1996, 743, 17-23. (c) Albers, G. W.; Clark, W. M.; Atkinson,
R. P.; Madden, K.; Data, J . L.; Whitehouse, M. J . Dose escalation
study of the NMDA glycine-site antagonist licostinel in acute
ischemic stroke. Stroke 1999, 30, 508-513.
(8) (a) Kulagowski, J . J .; Baker, R.; Curtis, N. R.; Leeson, P. D.;
Mawer, I. M.; Moseley, A. M.; Ridgill, M. P.; Rowley, M.;
Stansfield, I.; Foster, A. C.; Grimwood, S.; Hill, R. G.; Kemp, J .
A.; Marshall, G. R.; Saywell, K. L.; Tricklebank, M. D. 3′-
(Arylmethyl)- and 3′-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-
ones: Orally active antagonists of the glycine site on the NMDA
receptor. J . Med. Chem. 1994 37, 1402-1405. (b) Bristow, L. J .;
Hutson, P. H.; Kulagowski, J . J .; Leeson P. D.; Matheson, S.;
Murray, F.; Rathbone, D.; Saywell, K. L.; Thorn, L.; Watt, A.
P.; Tricklebank, M. D. Anticonvulsant and behavioral profile of
L-701,324, a potent, orally active antagonist at the glycine
modulatory site on the N-methyl-D-aspartate receptor complex.
J . Pharmacol. Exp. Ther. 1996, 279, 492-501.
(9) (a) Bare, T. M.; Smith, R. W.; Draper, C. W.; Sparks, R. B.;
Pullan, L. M.; Goldstein, J . M.; Patel, J . B. Pyridazino[4,5-b]-
quinolinediones: A series of novel glycine site NMDA antago-
nists with potent in vitro and in vivo properties. Abstracts of
Papers, 205th Meeting of the American Chemical Society; March
1993; Medi 79. (b) Takano, K.; Tatlisumak, T.; Formato, J . E.;
Carano, R. A. D.; Bergmann, A. G.; Pullan, L. M.; Bare, T. M.;
Sotak, C. H.; Fisher, M. Glycine site antagonist attenuates
infarct size in experimental focal ischemia. Stroke 1997, 28,
1255-1263. (c) Bare, T. M. Pyridazino[4,5-b]quinolinediones:
Novel glycine/N-methyl-D-aspartate antagonists for the treat-
ment of stroke. J . Heterocycl. Chem. 1998, 35, 1171-1186.
(10) For recent reports on investigation of in vivo active glycine
antagonists: (a) Carling, R. W.; Leeson, P. D.; Moore, K. W.;
Moyes, C. R.; Duncton, M.; Hudson, M. L.; Baker, R.; Foster, A.
C.; Grimwood, S.; Kemp, J . A.; Marshall, G. R.; Tricklebank, M.
D.; Saywell, K. L. 4-Substituted-3-phenylquinolin-2(1H)-ones:
Acidic and nonacidic glycine site N-methyl-D-aspartate antago-
nists with in vivo activity. J . Med. Chem. 1997, 40, 754-765.
(b) J imonet, P.; Ribeill, Y.; Bohme, G. A.; Boireau, A.; Cheve´,
M.; Damour, D.; Doble, A.; Genevois-Borella, A.; Herman, F.;
Imperato, A.; Guern, S. L.; Manfre´, F.; Pratt, J .; Randle, J . C.
R.; Stutzmann, J .-M.; Mignani, S. Indeno[1,2-b]pyrazin-2,3-
diones: A new class of antagonists at the glycine site of the
NMDA receptor with potent in vivo activity. J . Med. Chem. 2000,
43, 2371-2381. (c) Fray, M. J .; Bull, D. J .; Carr, C. L.; Gautier,
E. C. L.; Mowbray, C. E.; Stobie, A. structure-activity relation-
ships of 1,4-dihydro-(1H, 4H)-quinoxaline-2,3-diones as N-meth-
yl-D-aspartate (glycine site) receptor antagonists. 1. Heterocyclic
substituted 5-alkyl derivatives. J . Med. Chem. 2001, 44, 1951-
1962.
(12) (a) Nagata, R.; Tanno, N.; Kodo, T.; Ae, N.; Yamaguchi, H.;
Nishimura, T.; Antoku, F.; Tatsuno, T.; Kato, T.; Tanaka, H.;
Nakamura, M.; Ogita, K.; Yoneda, Y. Tricyclic quinoxalinedi-
ones: 5,6-Dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and
6,7-dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones as po-
tent antagonists for the glycine binding site of the NMDA
receptor. J . Med. Chem. 1994, 37, 3956-3968. (b) Nagata, R.;
Ae, N.; Tanno, N. Structure-activity relationships of tricyclic
quinoxalinediones as potent antagonists for the glycine binding
site of the NMDA receptor 1. Bioorg. Med. Chem. Lett. 1995, 5,
1527-1532. (c) Nagata, R.; Kodo, T.; Yamaguchi, H.; Tanno, N.
Structure-activity relationships of tricyclic quinoxalinediones
as potent antagonists for the glycine binding site of the NMDA
receptor 2. Bioorg. Med. Chem. Lett. 1995, 5, 1533-1536. (d)
Katayama, S.; Ae, N.; Nagata, R. Enzymatic resolution of
2-substituted tetrahydroquinolines. Convenient approaches to
tricyclic quinoxalinediones as potent NMDA-glycine antagonists.
Tetrahedron: Asymmetry 1998, 9, 4295-4299.
(13) For SM-18400 (1a ): (S)- 9-chloro-5-[p-aminomethyl-o-(car-
boxymethoxy)phenylcarbamoylmethyl]-6,7-dihydro-1H,5H-pyrido-
[1,2,3-de]quinoxaline-2,3-dione hydrochloride, see: (a) Nagata,
R.; Tanno, N.; Yamaguchi, H.; Kodo, T.; Ae, N.; Tanaka, H.;
Nakamura, M.; Ogita, K.; Yoneda, Y. Tricyclic quinoxalinedi-
ones: Highly in vivo active antagonists for the glycine binding
site of the NMDA recepter. Abstracts of papers, 210th National
Meeting of the American Chemical Society; Chicago, IL, August
1995; American Chemical Society: Washington, DC, 1995; Medi
150. (b) Tanaka, H.; Yasuda, H.; Kato, T.; Maruoka, Y.; Kawabe,
A.; Kawashima, C.; Ohtani, K.; Nakamura, M. Neuroprotective
and anticonvulsant actions of SM-18400, a novel strychnine-
insensitive glycine site antagonist. J . Cereb. Blood Flow Metab.
1995, 15, Suppl. 1, S431. (c) Yasuda, H.; Tanaka, H.; Ohtani,
K.; Kato, T.; Maruoka, Y.; Kawabe, A.; Kawashima, C.; Saka-
moto, H.; Tojo, S.; Nakamura, M. Neuroprotective effects of a
novel NMDA glycine site antagonist, SM-18400, in the rat model
of cerebral ischemia. Soc. Neurosci. Abstr. 1995, 21, 996. (d)
Maruoka, Y.; Ohno, Y.; Tanaka, H.; Yasuda, H.; Ohtani, K.;
Tamamura, C.; Nakamura, M. Effects of the novel tricyclic
quinoxalinedione derivatives, SM-18400 and its analogues, on
N-methyl-D-aspartate (NMDA) receptor-mediated synaptic trans-
mission in the isolated neonatal rat spinal cord in vitro. J pn. J .
Pharmacol. 1998, 76, 265-270. (e) Ohtani, K.; Tanaka, H.;
Yasuda, H.; Tamamura, C.; Maruoka, Y.; Ito, A.; Ohno, Y.;
Nakamura, M.; Noguchi, H. In vitro pharmacological properties
of the N-methyl-D-aspartate (NMDA) receptor glycine site
antagonist, SM-18400, Soc. Neurosci. Abstr. 1998, 24, 574. (f)
Ohtani, K.; Tanaka, H.; Yasuda, H.; Maruoka, Y.; Kawabe, A.;
Nakamura, M. Blocking the glycine-binding site of NMDA
receptors prevents the progression of ischemic pathology induced
by bilateral carotid artery occlusion in spontaneously hyperten-
sive rats. Brain Res. 2000, 871, 311-318.
(14) Hume, W. E.; Nagata, R. Synthesis of tricyclic azakynurenic
acids as a new class of NMDA-glycine antagonists using novel
Stille coupling reaction. Synlett 1997, 5, 473-474.
(15) Katayama, S.; Ae, N.; Nagata, R. Synthesis of tricyclic indole-
2-carboxylic acids as potent NMDA-glycine antagonists. J . Org.
Chem. 2001, 66, 3474-3483.
(16) Nagata, R.; Tanno, N.; Ae, N. Preparation of 1,3,4,5-tetrahy-
drobenz[cd]indole-2-carboxylate antagonists of glycine binding
in NMDA receptors. U.S. Patent 5,496,843, 1996.
(17) Mudryk, B.; Makosza, M.; Mudryk, B.; Makosza, M. Reactions
of organic anions. 156. A simple and efficient synthesis of alkyl
(2-nitroaryl)acetates and alkyl 2-(2-nitroaryl)propanoates via
vicarious nucleophilic substitution of hydrogen in nitroarenes
by carbanions of alkyl chloroacetates or alkyl 2-chloropro-
panoates. Synthesis 1988, 1007-1009.
(18) Tschaen, D. M.; Desmond, R.; King, A. O.; Fortin, M. C.; Pipik,
B.; King, S.; Verhoeven, T. R. An improved procedure for
aromatic cyanation. Synth. Commun. 1994, 24, 887-890.
(19) For the practical synthesis of SM-18400 aromatic fragment (5a )
which contains improved method to prepare 17: Kodo, T.;
Nishihara, T.; Nagata, R. Practical synthesis of the aniline part
of SM-18400, a tricyclic quinoxalinedione derivative, as a NMDA
glycine site antagonist. Abstracts of Papers, 219th National
Meeting of the American Chemical Society, San Francisco,
March 2000; American Chemical Society: Washington, DC,
2000; Orgn 610. For initial synthetic routes of 5a , also see ref
16.
(20) As a model reaction, m-iodophenol was coupled with 15h under
similar conditions to give the corresponding ether, 4-(2-(3-
iodophenoxy)propanoyl)morpholine. The absolute configuration
of the ether at R-position was unambiguously determined to be
S by X-ray crystallographic analysis. For similar reactions with
SN2 inversion, for example, see following papers: (a) Canceill,
J .; Collet, A.; Gabard, J .; Gottarelli, G.; Spada, G. P. Exciton
approach to the optical activity of C3-cyclotriveratrylene deriva-
tives. J . Am. Chem. Soc. 1985, 107, 1299-1308. (b) Biedermann,
J .; Leon-Lomeli, A.; Borbe, H. O.; Prop, G. Two stereoisomeric
(11) (a) Di Fabio, R.; Capelli, A. M.; Conti, N.; Cugola, A.; Donati,
D.; Feriani, A.; Gastaldi, P.; Gavirighi, G.; Hewkin, C. T.;
Micheli, F.; Missio, A.; Mugnaini, M.; Pecunioso, A.; Quaglia,
A. M.; Ratti, E.; Rossi, L.; Tedesco, G.; Trist, D. G.; Reggiani, A.
Substituted indole-2-carboxylates as in vivo potent antagonists
acting at the strychnine-insensitive glycine binding site. J . Med.
Chem. 1997, 40, 841-850. (b) Di Fabio, R.; Cugola, A.; Donati,
D.; Feriani, A.; Gaviraghi, G.; Ratti, E.; Trist, D. G.; Reggiani,
A. Identification and pharmacological characterization of
GV150526, a novel glycine antagonist as a potent neuroprotec-
tive agent. Drugs Future 1998, 23, 61-69. (c) Dyker, A. G.; Lees,
K. R. Safety and tolerability of GV150526 (a glycine site
antagonist at the N-methyl-D-aspartate receptor) in patients
with acute stroke. Stroke 1999, 30, 986-992. (d) Sacco, R. L.;
DeRosa, J . T.; Haley, E. C., J r.; Levin, B.; Ordronneau, P.;
Phillips, S. J .; Rundek, T.; Snipes, R. G.; Thompson, J . L. Glycine
antagonist in neuroprotection for patients with acute stroke:
GAIN Americas: a randomized controlled trial. J AMA 285, 2001,
1719-1728.